Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer
UMass Chan Affiliations
Department of Surgery, Division of Surgical OncologyDocument Type
Journal ArticlePublication Date
2016-02-01Keywords
Hyperthermic intraperitoneal chemoperfusion (HIPEC)carcinomatosis
cytoreductive surgery (CRS)
palliative surgery
quality of life (QOL)
Gastroenterology
Oncology
Surgery
Metadata
Show full item recordAbstract
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) is being used more and more frequently for the management of peritoneal carcinomatosis. Despite significant improvements in oncologic outcomes and the risk of complications and mortality, CRS/HIPEC remains one of the most morbid treatments offered for advanced cancers. Consequently CRS/HIPEC is still considered controversial by many, even in the setting of cancers that are potentially curable. However, as high volume surgical oncologists become more experienced with CRS/HIPEC, the potential role of "palliative CRS/HIPEC" in the management of peritoneal carcinomatosis is being raised. Given the often limited survival benefit expected after CRS/HIPEC, understanding the impact of the treatment on quality of life (QOL) needs to be an essential part of the decision to proceed and is critical to optimizing recovery afterwards. This article reviews the potential definitions of "palliative CRS/HIPEC" in various clinical contexts and describes the current state of the QOL experience after CRS/HIPEC.Source
J Gastrointest Oncol. 2016 Feb;7(1):112-21. doi: 10.3978/j.issn.2078-6891.2015.132. Link to article on publisher's siteDOI
10.3978/j.issn.2078-6891.2015.132Permanent Link to this Item
http://hdl.handle.net/20.500.14038/39948PubMed ID
26941989Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.3978/j.issn.2078-6891.2015.132